Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma (Q77585426)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

title

Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

B J Lynch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

G Komaromy-Hiller

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

I B Bronstein

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

J A Holden

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 November 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

1240-1245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Topoisomerase inhibitors. A review of their therapeutic potential in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Immunohistochemical Staining for DNA Topoisomerase II in Non-Hodgkin’s Lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Modulation of DNA Topoisomerase I Activity byp53

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2898%2990251-9

7 January 2021

10.1016/S0046-8177(98)90251-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9824101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference